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In haploidentical (haplo)-cord blood (CB) transplantations, early haplo donor engraftment serves as a myeloid
bridge to sustainable CB engraftment and is associated with early neutrophil recovery. The conditioning
regimens as published for haplo-cord protocols usually contain serotherapy, such as rabbit antithymocyte
globulin (ATG) (Thymoglobulin, Genzyme, Cambridge, MA). However, reducing or omitting serotherapy is an
important strategy to improve early immune reconstitution after transplantation. The need for serotherapy in
successful haplo-cord transplantation, deﬁned as having a haplo-derived myeloid bridge to CB engraftment,
has not been investigated before. Two consecutive cohorts of patients underwent transplantation with haplo-
CB. The ﬁrst group underwent transplantation with haplo-CB for active infection and/or an underlying
condition with expected difﬁcult engraftment without a conventional donor available. They received a single
unit (s) CB and haplo donor cells (CD34þ selected, 5  106 CD34þ/kg). The second cohort included patients
with poor-risk malignancies, not eligible for other treatment protocols. They received a sCB and haplo donor
cells (CD19/abTCR-depleted; 5  106 CD34þ/kg). Retrospectively in both cohorts, active ATG (Thymoglobulin)
levels were measured and postehematopoietic cell transplantation area under the curve (AUC) was calcu-
lated. The inﬂuence of ATG exposure for having a successful haplo-myeloid bridge (early haplo donor
engraftment before CB engraftment and no secondary neutropenia) and transplantation-related mortality
(TRM) were analyzed as primary endpoints. Twenty patients were included (16 in the ﬁrst cohort and 4 in the
second cohort). In 58% of evaluable patients, there was no successful haplo-derived myeloid bridge to CB
engraftment, for which a low post-transplantation ATG exposure appeared to be a predictor (P < .001). TRM
in the unsuccessful haplo-bridge group was 70%  16% versus 12%  12% in the successful haplo-bridge group
(P ¼ .012). In conclusion, sufﬁcient in vivo T depletion with ATG is required for a successful haplo-myeloid
bridge to CB engraftment.
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y for Blood andMarrow Transplantation.HCT has become safer over the last decade, the major
limitations remain relapse and transplantation-related
mortality (TRM), due to infection, viral reactivations/dis-
ease and graft-versus-host disease (GVHD). Unrelated cord
blood (CB) is an emerging alternative stem cell source for
HCT, as it has many advantages compared with conven-
tional sources, such as marrow and peripheral blood. These
include prompt availability and less stringent HLA-
matching criteria resulting in increased donor availability
[1] and a lower probability of GVHD, notwithstanding a
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hand, the cell number in the unit may be a limiting factor
associated with a prolonged neutropenia after CB trans-
plantation [5-7]. Prolonged neutropenia and lymphopenia
are important predictors for increased TRM [8-10].
Combining a CD34þ-selected haploidentical (haplo)-graft
with a full graft CB unit is a recently introduced cell support
procedure to make single CB (sCB) as donor source avail-
able to a larger proportion of patients [11-13]. It has been
shown that early haplo-donor cell engraftment can shorten
neutropenia and, as such, serve as a myeloid bridge until
followed by sustainable CB engraftment. In several reports,
this resulted in a fast (<14 days) neutrophil engraftment
[11-13]. In a Spanish study, 86% of patients ultimately
reached full CB donor chimerism within the time frame of
11 to 186 days after transplantation (median, 44 days),
suggesting that the haplo stem cell graft can only serve as
temporary bridge to full engraftment of an optimally
selected CB unit. Interestingly, the acute GVHD rates were
low [11,12]. Similar results were reported from a cohort in
Chicago [13] and a for a cohort of patients with aplastic
anemia [14]. In all of these described cohorts, antithymo-
cyte globulin (ATG) was part of the conditioning regimen.
Because of its long half-life, ATG will most certainly hamper
the early T, B, and NK cell reconstitution of the engrafted
donors and was, for that reason, reduced in dose in many
different (including CB) transplantation settings [15]. On
the other hand, ATG may support engraftment of
T celledepleted (haplo) products. Many speciﬁcally haplo
transplantation centers have moved to other strategies of
in vivo T cell depletion, such as post-HCT cyclophospha-
mide, in an attempt to still secure engraftment but improve
immune reconstitution, as well [16-18].
The early neutrophil recovery in haplo-cord trans-
plantation is caused by a secure haplo-derived myeloid
bridge until sustained CB engraftment occurs. Having used
more variable (and earlier) ATG timing in our center, wewere
able to investigate the impact of ATG exposure to the graft on
the success of this haplo-myeloid bridge based on serial
sampling and pharmacokinetic modeling [19].METHODS
Setting and Study Population
Since 2009 in the University Medical Center Utrecht, 2 haplo CB pro-
tocols were open.
Cohort A (single CB/CD34þeselected haplo)
Patients with any HCT indication with active infection and/or known
difﬁcult engraftment (severe aplastic anemia, osteopetrosis, hemophago-
cytic lympho-histiocytosis) and lacking a 10/10-matched sibling or 10/10-
matched unrelated donor (instantly) available, were candidates to be
enrolled in our sCB/CD34þeselected haplo protocol (open since June 2009).
Also, patients with only a sCB unit available with a lower than acceptable
nucleated cell (NC) count (minimum total nucleated cell dose: 2.5, 3, and
5  107 NC/kg in case of a 6/6, 5/6, or 4/6 HLA-matched unrelated CB unit,
respectively) were offered a sCB coinfused with a haploidentical graft
(5  106 CD34þ/kg) [20].
Cohort B (sCB/CD19 and abTCR-depleted haplo; NL31978.000.10)
Adults with poor-risk malignancies, not eligible for other treatment
protocols, received a sCB þ CD19/abTCR-depleted haploidentical donor cells
(also 5  106 CD34þ/kg). It was hypothesized that by using this depletion
method, the haplo-innate cells (NK and gamma-delta T cells) are coinfused,
which may have an additional antileukemic effect in the early phase after
transplantation [20,21]. No ATG was given in this protocol to preserve the
innate cells after transplantation.
All data were collected prospectively. Patients were enrolled in HCT and
research protocols only after written informed consent and institutional
ethical committee approval.Donor Selection and Stem Cell Processing
CB units were selected based on HLA typing (minimum 4/6 match on
intermediate resolution, HLA-A and -B on low resolution, and HLA-DR on
high resolution) and cell count, with a lower acceptable limit of 1.5107 NC/
kg before cryopreservation. Haplo donors were selected based on their
suitability to donate and undertake a peripheral blood stem cell collection
procedure with granulocyte colonyestimulating factor mobilization. The
related donors underwent stem cell mobilization with G-CSF (Filgrastim, 5
mcg/kg/day twice a day; Amgen, Thousand Oaks, CA, USA) for 4 consecutive
days. Apheresis was started on day 5 and continued until at least 8  106
CD34þ cells/kg recipient were harvested to take into account a loss with the
selection and depletion columns.
For cohort A, after peripheral blood collection from the haplo donor,
5  106 CD34þ cells/kg were selected and infused. CD34þ cells were posi-
tively selected using the Miltenyi CliniMACs CD34þ selection column (Mil-
tenyi Biotec GmbH , Bergisch Gladbach, Germany). For cohort B, Miltenyi
CD19/abTCR beads were used to deplete B cells and ab-T cells from the haplo
donor graft, collecting also 5106 CD34þ cells/kg recipient. For cohort B, the
maximum allowed number of abT cells in the graft was < 5  104/kg. The
haploidentical graft was freshly infused within 1 to 5 hours after the infu-
sion of the CB unit in both protocols.
Transplantation Details, Conditioning Regimen, and Supportive Care
The main myeloablative regimen contained Busulfan (Busilvex; Pierre
Fabre, Boulogne-Billancourt, France) with therapeutic drug monitoring
(target area under the curve [AUC] 90 to 95 mg*hour/L and ﬂudarabine [Flu]
160 mg/m2). A reduced-intensity alternative (adults) was Flu [cumulative
dose 160 mg/m2]/cyclophosphamide [60 mg/kg]/total body irradiation
2  200 cGy. For second HCTs (cohort A): Treosulfan (42 g/m2 in 3 days
[Medac, Wedel, Germany], Flu 160 mg/m2).
Serotherapy (in cohort A) included Thymoglobulin (Genzyme Cambridge,
MA; 10 mg/kg in 4 consecutive days: -9,-8,-7,-6). Alemtuzumab (Campath-
1H; Genzyme) was given for second transplantations and patients previously
receiving Thymoglobulin as part of the therapy for severe aplastic anemia.
Active Thymoglobulin (ATG) and alemtuzumab levels were measured
retrospectively as described below and post-HCT serotherapy exposure
(AUC) was determined [22]. Patients receiving alemtuzumab were not
included in the analysis but are brieﬂy described.
Patients received GVHD prophylaxis with cyclosporine A (trough level
200 to 250 mg/L) from day 2 to 3 months for malignant indications
(6 months for nonmalignant). Prednisone 1 mg/kg was administered from
days 0 to 30 as engraftment syndrome prophylaxis in pediatric patients.
Patients received G-CSF (Filgrastim) 10 mcg/kg/day once daily i.v. from
day þ7 until neutrophil engraftment > 2  109/L.
As antibacterial prophylaxis, patients received ciproﬂoxacin and cefa-
zolin until neutrophil engraftment (>500/uL) and recovery of mucositis.
Patients received viral prophylaxis with acyclovir and Pneumocystis Jiroveci
prophylaxis with cotrimoxazole until 6 months after HCT. Seven of 16 pa-
tients in cohort A were on antifungal therapy because of active ongoing
fungal infection. Therapy was preferably based on resistance patterns from
fungal isolates. If not treated therapeutically, patients were considered to be
at high risk for fungal infection and received prophylaxis with voriconazole
as the ﬁrst choice (trough level >1 mg/dL) [23,24]. Concomitant treatments
of the adult patients have been described in more detail elsewhere [25,26].
Post-transplantation Follow-Up
Monitoring for Epstein-Barr virus, cytomegalovirus, and adenovirus DNA
positivity was performed weekly as described elsewhere [27]. Chimerism
studies were performed on unfractionated peripheral blood samples (L > .4)
and repeated every 2 to 4 weeks until > 95% CB chimerism was observed.
The haplo-myeloid bridge to CB engraftment was considered successful if
haplo-derived neutrophil engraftment would precede CB engraftment
without an interval of cytopenia. Graft failure (GF) was deﬁned as either (1)
early loss of haplo and no engraftment of the CB, or (2) secondary loss of both
grafts. Death without disease progression or relapse was considered trans-
plantation related. Toxicity was scored according to National Cancer institute
Toxicity Criteria; acuteGVHD (aGVHD)was scored according to theGlucksberg
criteriawith the caveat of late aGVHD occurring after day 100, as described by
the National Institutes of Health consensus guidelines [28,29]. Chronic GVHD
was deﬁned as stated in National Institutes of Health guidelines.
Analytical Assay
Active ATG, capable of binding to human T lymphoma cell line (HUT)
cells, was measured using a quantitative ﬂow cytometry assay [22,30]. In
short, HUT-78 T cells were incubated with patient serum and subsequently
with labeled ﬂuorescent goat antirabbit IgG. For standard reference, HUT
cells were incubated with known amounts of ATG (Thymoglobulin, Gen-
zyme). Active ATG is measured in arbitrary units (AU), where the lower limit
of quantiﬁcation was .1 AU/mL.
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Post-transplantation ATG-exposure (AUC: AU*day/L) has been shown to
be of strong inﬂuence on immune reconstitution for HCT in pediatric pa-
tients and is investigated as a predictive factor for successful haplo-cord
transplantation [19]. Primary endpoints included (1) successful haplo-
myeloid bridge to sustained CB engraftment, which was deﬁned as neutro-
phil engraftment without secondary neutropenia occurring, and at the time
of engraftment a combined (haplo > CB) chimerism that over time switches
to full (>95%) CB donor chimerism, and (2) TRM.
Other endpoints included overall survival (OS), GF, aGVHD, neutrophil
and platelet engraftment (95% conﬁdence intervals of neutrophil
engraftment > 500/uL within 60 days, thrombocyte engraftment to
20  109/L within 180 days), and > 95% cord blood donor chimerism.
Statistical Analyses
For statistical analysis, follow-up time is the time to the last assessment
for surviving patients or to the time of death. Logistic regressionwas used to
visualize and analyze the binary data and to depict the chance of successful
myeloid bridge as a function of post-HCT active ATG AUC. Kaplan-Meier
estimates are calculated for nonrelapse mortality. We performed regres-
sion analysis on the primary endpoints for the variables of post-HCT ATG
exposure, CB NC dose, stem cell transplantation number, HLAmismatch, age,
and underlying condition. The association of a successful haplo-derived
myeloid bridge for the TRM and GF were analyzed. Statistical analysis was
performed using SPSS, (IBM, Inc.) software packages version 19.0 and R
version 3.0.1. For pharmacokinetic analyses NONMEM 7.2 (Icon, Ellicott City,
MD) was used.
RESULTS
Twenty-two patients were treated with haplo-CB trans-
plantations (Table 1). The median age was 16.5 years (range,
.25 to 59.1). Eighteen patients (15 children, 3 adults; 14 with
active infection, 1 previous GF, 3 low NC-dosed CB) were
included in cohort A: 11 patients had a nonmalignant indi-
cation for transplantation (7 immunodeﬁciencies, 1 osteo-
petrosis, 3 severe aplastic anemia) and 7 had a malignant
indications (1 non-Hodgkin lymphoma, 1 acute myeloidTable 1
Patient Characteristics
Patient No. Age Diagnosis SCT No. Indication for Haplocor
1 17 yr NHL-CR3 First Ongoing infection (Asp
2 1 yr HLH First Ongoing infection (Fus
3 16 yr AML-CR2 First Ongoing infection (Asp
4 17 yr CID, autoimmune
enteropathy
First SIB cord low cell numb
viral infections, very hi
5 3 mo Osteopetrosis Second Difﬁcult engraftment, p
and treatment related
6 9 yr ALL-CR2 First Ongoing infection (Asp
7 14 yr CID: Nemo deﬁciency First Ongoing infection (Asp
8 41 yr Aplastic anemia First No conventional donor
9 18 yr X-linked CGD First Ongoing colitis, unkno
low dose CB unit
10 4 yr ALL-CR1 First Ongoing infection (Asp
11 6 yr CGD First Ongoing infection (Asp
12 15 yr CID First Ongoing infection (Asp
13 15 yr Aplastic anemia First No conventional donor
14 17 yr ALL-CR3 First Urgency, toxicity issue
ongoing infection (Asp
15 12 yr MDS-Raeb-T Second Ongoing infection (Asp
16 52 yr MDS þ HIV First Ongoing infection, no d
17 49 yr Third relapse ALL Second No available MUD don
18 46 yr Second allo-sct CMML Second Second relapse
19 38 yr Second relapse Hodgkin First Second relapse
20 59 yr Second allo relapse AML Second Second relapse, no con
21 5 yr Kostmann, BM-failure Second Ongoing infection
22 17 yr Aplastic anemia First No conventional donor
NHL indicates non-Hodgkin lymphoma; CR, complete remission; HLH, hereditary
nodeﬁciency; SIB, sibling; ALL, acute lymphatic leukemia; Nemo, NF-kB-essential
zoster virus; CGD, chronic granulomatous disease; MDS, myelodysplastic syndrome
virus; MUD, matched unrelated donor; allo, allogeneic, BM, bone marrow.
All patients who underwent transplantation with haplo-CB are shown. Patients who
shown in grey.leukemia, 3 acute lymphoid leukemia, 2 myelodysplastic
syndrome). Three patients received haplo-CB as a second
transplantation. Four patients with poor-risk malignant dis-
ease (Table 1) underwent transplantation in cohort B. For 3 of
them, it was their second transplantation.
The median CB cell dose at selectionwas 4.13 107 NC/kg
(range, 2.0 to 20.0) and 2.0  105 CD34þcells/kg (range, .2 to
6.2). Six patients received a 6/6-matched CB unit, 12 patients
received a 5/6 CB unit, and 4 patients a 4/6 CB unit.
In cohort A, 2 patients received alemtuzumab (Campath-
1H) instead of ATG in their regimen (.5 mg/kg and .75 mg/kg)
and 1 received no serotherapy. In cohort B, per protocol, none
of the patients received serotherapy. For analysis of the
Thymoglobulin impact, we only included patients in the 2
protocols who received either Thymoglobulin as serotherapy
or no serotherapy at all (n ¼ 20).
The minimum follow-up of the patients who remained
alive is 18 months.Primary Endpoints
One patient (patient number 5) was not evaluable for the
primary endpoint of having a successful myeloid bridge
because of early death after HCT (day þ14). In 58% (11 of 19)
of evaluable patients, there was no successful haplo-derived
myeloid bridge to CB engraftment. None of the patients
treated without ATG in the conditioning regimen (n¼ 5) had
a successful haplo-myeloid engraftment. The median post-
HCT active ATG AUC of patients receiving ATG was 17
AU*day/L (range, 0 to 139). Evaluating patients receiving
either ATG (n ¼ 14) or no serotherapy (n ¼ 5, ATG AUC ¼ 0)
altogether, only ATG exposure appeared to be a predictor
(P < .001) for successful haplo-myeloid engraftmentd Cohort Serotherapy Haplo Selection
Method
ergillus) A ATG CD34þ selection
arium, pseudomonas) A ATG CD34þ selection
ergillus) A ATG CD34þ selection
er, multiple
gh risk of GVHD
A ATG None (10/10 match)
rogression of disease
morbidity in ﬁrst SCT
A ATG CD34þ selection
ergillus) A ATG CD19/CD3
depleted
ergillus), CMV, EBV, VZV A ATG CD34þ selection
; aplastic for years A ATG CD34þ selection
wn infections, A ATG CD34þ selection
ergillus) A ATG CD34þselection
ergillus) A ATG CD34þ selection
ergillus) A ATG CD34þ selection
A ATG CD34þ selection
s ALL therapy,
ergillus)
A ATG CD34þ selection
ergillus) A no CD34þ selection
onor A ATG CD34þ selection
or B no CD19/abTCR depletion
B no CD19/abTCR depletion
B no CD19/abTCR depletion
ventional donor B no CD19/abTCR depletion
A Campath-1H CD34þ selection
, urgency A Campath-1H CD34þ selection
lymphohistiocytosis; AML, acute myeloid leukemia; CID, combined immu-
modulator; CMV, cytomegalovirus; EBV, Epstein-Barr virus, VZV, varicella
; RAEB, refractory anemia with excess blasts; HIV, human immunodeﬁciency
had alemtuzumab in the regimen who were excluded from the analysis are
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haplo-donor-derived myeloid bridge (n ¼ 11) was 70%  16%
versus 12%  12% in the group with a successful myeloid
bridge (n ¼ 8, P ¼ .012) (Figure 1C). Analyzing only the pa-
tients in cohort A, this strong association between post-HCT
ATG AUC and successful haplo-myeloid engraftment
remained (P < .001).
For the 2 patients in cohort Awhowere excluded because
they received alemtuzumab as their serotherapy agent (pa-
tient numbers 21 and 22) (Table 1), we observed the same
association. One patient had a very high alemtuzumab
exposure and had a successful haplo-derivedmyeloid bridge,
and the other patient had a very low exposure and did not
have a successful myeloid bridge. He, fortunately, had an
early CB engraftment. Both patients are alive and well.
Secondary Endpoints
Overall, in our haplo-cord cohort there was a cumulative
incidence (CI) of neutrophil recovery of 95% with a median of
13 days (range, 9 to 52). The CI of platelet recovery to
50  109/L at day 180 was 78% for evaluable patients. The
median time to reach platelet recovery to 50  109/L was 26
(range, 11 to 88) days. In 87% patients without a successful
myeloid bridge, there was a primary or secondary GFFigure 1. ATG exposure and outcome of haplo-cord transplantation. (A) Post-HCT AUC
transplantation, depicted for patients who did or did not have a successful haplo-deriv
the chance of successful haplo-derived myeloid bridge as a function of the post-HCT AU
log-rank analysis for the probability of (C) TRM and (D) OS for patients with and witinvolving the ultimate loss of both grafts, explaining the high
TRM. In the group with a successful myeloid bridge, we only
observed a graft loss in 1 of 8 patients. OS in the patients
receiving either Thymoglobulin or no serotherapy at all was
42%  12% after a median follow-up of 254 days (range, 14 to
2393). Corresponding with TRM, OS was much lower in pa-
tients without a successful myeloid bridge (OS of 25%  15%
versus 82%  12% in patients with a successful haplo-derived
myeloid bridge (P ¼ .021) (Figure 1D).
In an attempt to exclude other causes of donor failure, the
recipients with a loss of the haplo- and/or CB graft were
tested for the development of HLA antibodies, which were
not detected in any of them.
We evaluated the haplo to CB chimerism switch that is
known to occur over time in haplo CB transplantations. Early,
at 1 month after HCT, patients who undergo transplantation
in the context of ATG (n ¼ 14 with > 1-month survival)
showed signs of signiﬁcant haplo engraftment, with an initial
chimerism of > 80% haplo donor in 11 of 14 patients. Eighty-
three percent (10 of 12) of evaluable patients with more than
3 months of follow-up after haplo CB transplantation
reached full donor CB chimerism (>95%) at a median of
90 days (range, 23 to 925) after HCT. In contrast, in patients
without ATG exposure (n ¼ 5), there was an early loss ofdorof active ATG (Thymoglobulin) of patients who underwent a haplo-cord blood
ed myeloid bridge to cord blood engraftment. (B) A logistic regression depicting
C of active ATG. (C and D) Kaplan-Meier curves representing a comparison and
hout a successful haplo donor-derived myeloid bridge.
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blood. Instead, patients without ATG exposure showed full
donor CB chimerism at a median of 24 days (range, 21 to 76)
after HCT; however, most with low neutrophil counts.
Toxicity Endpoints
The CI of GVHD grade II to IV was 40%  12% (5 patients
grade II, 2 patients grade III). However, speciﬁcally in patients
treated without ATG, aGVHD grade II to IV occurred in 4 of 5
patients (grade II [n ¼ 2], grade III [n ¼ 1], grade IV [n ¼ 1]).
All had 100% CB donor chimerism at the time of GVHD
diagnosis. However, because of the small sample size and “no
ATG” occurring more in older patients with refractory ma-
lignancy treated in cohort B, deﬁnite conclusions cannot be
made on this association.
No cases of veno-occlusive disease or other severe toxicity
were observed. Four of the 7 patients with ongoing proven
fungal infection were cured and antifungals were stopped
successfully. In 2 other patients, fungal infections continued
to be controlled with antifungals, which were continued
until CD4 cell counts are recovered > 200  106/L. In 10 of 19
patients, viral reactivation of cytomegalovirus (n ¼ 9) or
Epstein Barr virus (n ¼ 1) occurred, which were successfully
controlled with antivirals. Of the patients in cohort B with
poor graft function and GVHD, 1 developed an Aspergillus
infection.
DISCUSSION
Here, we describe the patients treated with haplo-CB
transplantation in our center, in which different regimens
for ATG dosing had been used. We observed a larger per-
centage of GF than previously published and investigated the
role of ATG exposure to the security of the sequential
engraftment of haplo and CB donors in the haplo-CB setting.
We ﬁnd that the risk of nonengraftment of the haplo
donor is substantially increased below a deﬁned threshold of
ATG exposure. Early rejection of the haplo donor was also
associated with a primary or secondary failure of sustainable
CB engraftment, potentially due to complex graft-versus-
graft effects or associated with the high-risk nature of the
patient selection, not allowing the wait for a long CB
engraftment period. Consequently, we observed a higher
TRM and lower OS, most likely due to prolonged neu-
tropenia. We hypothesize, based on the chimerism data,
which show a dominant CB signal in these cases, that
rejection of the haplo donor is mediated by T cells from the
CB unit.
Engraftment problems have not previously been raised as
a major complication in the earlier described haplo-CB co-
horts and the reported GF rates are between 7% and 15%.
However, all published studies describing haplo-CB trans-
plantation were performed in adults in the context of ATG
administered shortly before CB graft infusion. We have
shown previously that with current dosing regimens with a
ﬁxed dose depicted as milligram per kilogram, higher post-
HCT ATG exposures are found in higher body weight in-
dividuals and that small amounts of ATG severely hamper
post-transplantation immune reconstitution [31]. Adult re-
cipients are, therefore, more likely to have complete deple-
tion of their CB graft using the haplo sCB regimens available.
We hypothesize that in vivo T celledepleted CB is less strong
and more likely to not outcompete the T celledepleted haplo
graft, which is infused at the same time.
We conﬁrm that in the context of sufﬁcient serotherapy
exposure, coinfusion of a CD34þ-selected haplo graft with CBtransplantation can be a safe and effective treatment option
even in a group of very higherisk patients (including pa-
tients with higher nonengraftment risks) with a low GVHD
risk. As reported by others and observed in our cohort A, the
majority of successfully engrafted patients switch to full CB
chimerism within 4 months, followed by an ultimately
normal immune recovery and repertoire [32]. However, this
is delayed compared with the situation without serotherapy
(exposure) in the conditioning regimen and completely
dependent on thymic output after > 6 months after HCT
[27,32,33]. Others have shown this successful CB engraft-
ment in the haplo-cord setting regardless of the cell number
of the CB, again arguing for a severe imbalance between the 2
grafts [11,34]. Most likely, the imbalance of a
T cellecompetent CB unit cotransplanted with a severely
immune-depleted haplo unit (CD34 selection) facilitates
maintenance of the CB unit. In double CB transplantations,
dominant CB T cell clones have also been suggested to be
involved in graft rejection of the subdominant unit [35,36].
Our observation has important implications for broad-
ening the application of haplo-CB transplantations. Haplo-CB
transplantations have been proposed as a method to use CB
units with suboptimal cell numbers. This is in particular of
interest for HLA-minority subgroups with a low probability
of ﬁnding well-matched CB units [37] and for optimizing the
use of highly matched, non inherited maternal antigens
(NIMA) matched/mismatched CB or CB with speciﬁc genetic
proﬁles [38,39]. Also, low ATG exposure may risk engraft-
ment in (double) CB expansion protocols where the CD34-
negative T cellecontaining fraction of the expanded CB unit
is not infused [40,41]. Furthermore, haplo-CB transplantation
is increasingly being proposed as a cell support mechanism
to drive engraftment with the goal of shortening hospital
admission time and lowering costs [42,43]. Platelet engraft-
ment is fast in haplo-CB studies, suggesting earlier trans-
fusion independence [11,13]. Most interestingly, both
neutrophil and platelet engraftment rates are faster than
those reported in large double CB transplantation studies
[44-46]. The advantage of the haplo donor here is the large
number of stem cells that can be infused this way.
Haplo-CB protocols have been associated with low GVHD
risks [11,13]. In our dataset, there is a striking difference
between the low aGVHD incidence in patients treated with
ATG (20%) and without ATG (75%, of which one-half were
grade III). All patients with aGVHD had 100% CB chimerism
at the time of aGVHD, suggesting the development of GVHD
was not due to the alternative donor selection method used
for the haplo donor. Instead, the nondepleted CB graft in the
context without ATG is probably responsible for causing
GVHD. This is consistent with our ﬁndings on the impact of
Thymoglobulin in sCB transplantation, where much higher
rates of GVHD were found in the patients who underwent
transplantation without Thymoglobulin in the conditioning
regimen [27].
Although limited by small sample size, omitting sero-
therapy (eg, ATG) in the haplo-CB setting appears to be
strongly associated with failure of the haplo-myeloid-bridge
to CB engraftment, resulting in high TRM rates and low
survival. Being then conﬁned to using ATG with a high post-
HCT exposure, however, implies in vivo T depletion of the CB
graft and resulting in slow T cell reconstitution, mostly
dependent on thymic recovery [27]. Another strategy for
patients with ongoing infection where an ultra-short neu-
tropenic period in conjunction with a predictable early im-
mune reconstitution is required could be bridging the time to
C.A. Lindemans et al. / Biol Blood Marrow Transplant 21 (2015) 1839e18551844engraftment with granulocyte transfusions. A newer poten-
tially interesting development is the development of CB
expansion protocols that not only infuse the expanded stem
cell population for early engraftment but also include the
CD34-negative (T cellecontaining) fraction in the graft to
retain immune reconstitution capacity.
In adults, haplo-CB with serotherapy appears to be a good
alternative to matched unrelated donors [47] with favorable
outcomes even in elderly patients [48]. Being readily avail-
able, the haplo-CB platform has been proven useful when
timing is of the essence and/or when only sCB and haplo
donors are available. Haplo-CB can, therefore, speciﬁcally
beneﬁt patients without conventional donors and HCT pa-
tients with ongoing bacterial or fungal infection, but sufﬁ-
cient in vivo T depletion with ATG is required for its success.
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Rejectiona b s t r a c t
Transfusion-related alloimmunization is a potent barrier to the engraftment of allogeneic hematopoietic stem
cells in patients with nonmalignant diseases (NMDs). Memory T cells, which drive alloimmunization, are rela-
tively resistant to commonly used conditioning agents. Alefacept, a recombinant leukocyte function antigen-3/
IgG1 fusion protein, targets CD2 and selectively depletes memory versus naive T cells. Three multiply trans-
fusedpediatric patientswithNMDreceiveda short courseofhigh-dose i.v. alefacept (.25mg/kg/dose ondays40
and9 and .5mg/kg/dose ondays33,26,19, and12) before undergoingunrelated allogeneic transplant in
the setting of reduced-intensity pretransplant conditioning and calcineurin inhibitorebased post-transplant
graft-versus-host disease (GVHD) prophylaxis. Alefacept infusions were well tolerated in all patients. Periph-
eral bloodﬂowcytometrywas performed at baseline and during and after alefacept treatment. As expected, after
the 5 weekly alefacept doses, each patient demonstrated selective loss of CD2hi/CCR7/CD45RA effector
memory (Tem) and CD2hi/CCR7þ/CD45RA central memory (Tcm) CD4þ and CD8þ T cells with relative preser-
vation of the CD2lo Tem and Tcm subpopulations. In addition, depletion of CD2þ natural killer (NK) cells also
occurred. Neutrophil recovery was rapid, and all 3 patients had 100% sorted (CD3/CD33) peripheral blood donor
chimerismbydayþ100. Immune reconstitution (byabsolute neutrophil,monocyte, and lymphocyte counts)was
comparablewitha cohortofhistorical control patients. All 3 patients developedGVHDbut are all nowoff immune
suppression and >2 years post-transplant with stable full-donor engraftment. These results suggest that alefa-
cept athigherdosingcandeplete bothmemoryTcells andNKcells and that incorporatingCD2-targeteddepletion
into a reduced-intensity transplant regimen is feasible and safe in heavily transfused patients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the only curative therapy for many pediatric pa-
tients with life-threatening nonmalignant diseases (NMDs)
[1-14]. Rejection remains an impediment to successful
transplantation in many of these disorders, especially in
